Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - JOUR
LB  - 1.
AU  - Grossman, I
TI  - Routine pharmacogenetic testing in clinical practice: dream or reality?
J2  - Pharmacogenomics
PY  - 2007
VL  - 8
SP  - 1449
EP  - 1459
ER  - 
TY  - CHAP
LB  - 2.
AU  - Palomaki, G
AU  - McClain, M
AU  - Haddow, J
TI  - ACCE reviews of genetic tests: BRC1, BRC2, and CFTR
A2  - Gwinn, M
A2  - Bedrosian, B
A2  - Ottmann, D
A2  - Khoury, M
T2  - Genomics and population health
CY  - Atlanta, GA
PB  - Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention
PY  - 2005
SP  - 27
EP  - 33
UR  - http://origin.cdc.gov/genomics/activities/ogdp/2005/chap05.htm
ER  - 
TY  - JOUR
LB  - 3.
AU  - Thakur, M
AU  - Grossman, I
AU  - McCrory, D
AU  - Orlando, L
AU  - Steffens, D
AU  - Cline, K
TI  - Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors
J2  - Genet Med
PY  - 2007
VL  - 9
SP  - 826
EP  - 835
ER  - 
TY  - JOUR
LB  - 4.
AU  - Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
TI  - Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors
J2  - Genet Med
PY  - 2007
VL  - 9
SP  - 819
EP  - 825
ER  - 
TY  - ELEC
LB  - 5.
AU  - Roche Molecular Systems
TI  - US Food and Drug Administration 510(k) substantial equivalence determination decision summary for Roche AmpliChip CYP450 microarray for identifying CYP2C19 genotype (510(k) Number k043576)
PY  - 2005
UR  - www.fda.gov/cdrh/reviews/k043576.pdf
M1  - 19 April 2006
ER  - 
TY  - JOUR
LB  - 6.
TI  - Roche’s AmpliChip test gets EU approval
J2  - Pharmacogenomics
PY  - 2004
VL  - 5
SP  - 763
ER  - 
TY  - JOUR
LB  - 7.
AU  - de Leon, J
AU  - Susce, M
AU  - Pan, R
AU  - Koch, W
AU  - Wedlund, P
TI  - Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and Dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness
J2  - J Clin Psychopharmacol
PY  - 2005
VL  - 25
SP  - 448
EP  - 456
ER  - 
TY  - JOUR
LB  - 8.
AU  - Pirmohamed, M
AU  - Park, BK
TI  - Cytochrome P450 enzyme polymorphisms and adverse drug reactions
J2  - Toxicology
PY  - 2003
VL  - 192
SP  - 23
EP  - 32
ER  - 
TY  - ELEC
LB  - 9.
AU  - National Library of Medicine Genetics Home Reference
TI  - CYP gene family
UR  - http://ghr.nlm.nih.gov/geneFamily=cyp
M1  - 29 July 2008
ER  - 
TY  - JOUR
LB  - 10.
AU  - Blower, PR
TI  - 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications
J2  - Cancer J
PY  - 2002
VL  - 8
SP  - 405
EP  - 414
ER  - 
TY  - JOUR
LB  - 11.
AU  - de Leon, J
AU  - Armstrong, SC
AU  - Cozza, KL
TI  - Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19
J2  - Psychosomatics
PY  - 2006
VL  - 47
SP  - 75
EP  - 85
ER  - 
TY  - JOUR
LB  - 12.
AU  - Kirchheiner, J
AU  - Brosen, K
AU  - Dahl, ML
AU  - Gram, LF
AU  - Kasper, S
AU  - Roots, I
TI  - CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages
J2  - Acta Psychiatr Scand
PY  - 2001
VL  - 104
SP  - 173
EP  - 192
ER  - 
TY  - JOUR
LB  - 13.
AU  - Kirchheiner, J
AU  - Nickchen, K
AU  - Bauer, M
AU  - Wong, M-L
AU  - Licinio, J
AU  - Roots, I
TI  - Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
J2  - Mol Psychiatry
PY  - 2004
VL  - 9
SP  - 442
EP  - 473
ER  - 
TY  - JOUR
LB  - 14.
AU  - Arranz, MJ
AU  - de Leon, J
TI  - Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
J2  - Mol Psychiatry
PY  - 2007
VL  - 12
SP  - 707
EP  - 747
ER  - 
TY  - ELEC
LB  - 15.
AU  - The Doctors Laboratory
TI  - Pharmacogenetics: using genotyping in the development of personalised medicine
TI  - TDL Lab Report
PY  - 2005
UR  - www.tdlpathology.com/
ER  - 
TY  - JOUR
LB  - 16.
AU  - Ingelman-Sundberg, M
AU  - Sim, SC
AU  - Gomez, A
AU  - Rodriguez-Antona, C
TI  - Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
J2  - Pharmacol Ther
PY  - 2007
VL  - 116
SP  - 496
EP  - 526
ER  - 
TY  - JOUR
LB  - 17.
AU  - Kim, E
AU  - Yu, KS
AU  - Cho, JY
AU  - Shin, YW
AU  - Yoo, SY
AU  - Kim, YY
TI  - Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study
J2  - Hum Psychopharmacol
PY  - 2006
VL  - 21
SP  - 519
EP  - 528
ER  - 
TY  - JOUR
LB  - 18.
AU  - Cupp, M
AU  - Tracey, T
TI  - Cytochrome P450: new nomenclature and clinical implications
J2  - Fam Phys
PY  - 1998
VL  - 57
SP  - 107
EP  - 116
ER  - 
TY  - JOUR
LB  - 19.
AU  - Kirchheiner, J
TI  - CYP2D6 phenotype prediction from genotype: which system is best
J2  - Clin Pharmacol Ther
PY  - 2008
VL  - 83
SP  - 225
EP  - 227
ER  - 
TY  - JOUR
LB  - 20.
AU  - Gaedigk, A
AU  - Simon, S
AU  - Pearce, R
AU  - Bradford, LD
AU  - Kennedy, M
AU  - Leeder, J
TI  - The CYP2D6 activity score: translating genotype information into qualitative measure of phenotype
J2  - Clin Pharmacol Ther
PY  - 2008
VL  - 83
SP  - 234
EP  - 242
ER  - 
TY  - JOUR
LB  - 21.
AU  - Cai, WM
AU  - Chen, B
AU  - Zhang, WX
TI  - Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population
J2  - Clin Pharmacol Ther
PY  - 2007
VL  - 81
SP  - 95
EP  - 98
ER  - 
TY  - JOUR
LB  - 22.
AU  - Bradford, LD
TI  - CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
J2  - Pharmacogenomics
PY  - 2002
VL  - 3
SP  - 229
EP  - 243
ER  - 
TY  - JOUR
LB  - 23.
AU  - Garcia-Barcelo, M
AU  - Chow, LY
AU  - Chiu, HF
AU  - Wing, YK
AU  - Lee, DT
AU  - Lam, KL
TI  - Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population [erratum appears in Clin Chem 2000; 46: 1873]
J2  - Clin Chem
PY  - 2000
VL  - 46
SP  - 18
EP  - 23
ER  - 
TY  - BOOK
LB  - 24.
AU  - Matchar, D
AU  - Thakur, M
AU  - Grossman, I
AU  - McCroy, D
AU  - Orlando, L
AU  - Steffens, D
TI  - Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with SSRIs
CY  - Rockville, MD
PB  - Agency for Healthcare and Research Quality
PY  - 2006
ER  - 
TY  - JOUR
LB  - 25.
AU  - Zackrisson, A
AU  - Holmgren, P
AU  - Gladh, A
AU  - Ahlner, J
AU  - Lindblom, B
TI  - Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions
J2  - Eur J Pharmacol
PY  - 2004
VL  - 60
SP  - 547
EP  - 552
ER  - 
TY  - ELEC
LB  - 26.
AU  - Human Cytochrome P450 (CYP) Allele Nomenclature Committee
TI  - Allele nomenclature for cytochrome P450 enzymes
UR  - www.cypalleles.ki.se/
M1  - 30 July 2008
ER  - 
TY  - ELEC
LB  - 27.
AU  - The Doctors Laboratory
TI  - AmpliChip CYP450 test: breast cancer and tamoxifen response
TI  - TDL Lab Report
PY  - 2007
UR  - www.tdlpathology.com/
ER  - 
TY  - ELEC
LB  - 28.
AU  - National Health Service (UK)
TI  - Mental Health National Service Framework
PY  - 1999
UR  - www.dh.gov.uk/assetRoot/04/07/72/09/04077209.pdf
M1  - 2008
ER  - 
TY  - GEN
LB  - 29.
AU  - World Health Organization
TI  - ICD-10: the ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines
CY  - Geneva
PB  - World Health Organization
PY  - 1992
ER  - 
TY  - JOUR
LB  - 30.
AU  - Osby, U
AU  - Correia, N
AU  - Brandt, L
AU  - Ekbom, A
AU  - Sparen, P
TI  - Mortality and causes of death in schizophrenia in Stockholm county, Sweden
J2  - Schizophr Res
PY  - 2000
VL  - 45
SP  - 21
EP  - 28
ER  - 
TY  - JOUR
LB  - 31.
AU  - Saha, S
AU  - Chant, D
AU  - McGrath, J
TI  - A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?
J2  - Arch Gen Psychiatry
PY  - 2007
VL  - 64
SP  - 1123
EP  - 1131
ER  - 
TY  - JOUR
LB  - 32.
AU  - Palmer, BA
AU  - Pankratz, VS
AU  - Bostwick, JM
TI  - The lifetime risk of suicide in schizophrenia: a reexamination [see comment]
J2  - Arch Gen Psychiatry
PY  - 2005
VL  - 62
SP  - 247
EP  - 253
ER  - 
TY  - ELEC
LB  - 33.
AU  - Department for Work and Pensions
TI  - Prevalence of schizophrenia
UR  - www.dwp.gov.uk/medical/med_conditions/major/schizophrenia/prevalence_schizophrenia.asp
M1  - 26 June 2008
ER  - 
TY  - JOUR
LB  - 34.
AU  - Goldner, EM
AU  - Hsu, L
AU  - Waraich, P
AU  - Somers, JM
TI  - Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature
J2  - Can J Psychiatry
PY  - 2002
VL  - 47
SP  - 833
EP  - 843
ER  - 
TY  - ELEC
LB  - 35.
AU  - MIND
TI  - Statistics 1: how common is mental distress?
PY  - 2008
UR  - www.mind.org.uk/Information/Factsheets/Statistics/Statistics+1.htm#ftnref36
M1  - 28 July 2008
ER  - 
TY  - BOOK
LB  - 36.
AU  - Jablensky, A
AU  - Sartorius, N
AU  - Ernberg, G
AU  - Anker, M
AU  - Korten, A
AU  - Cooper, JE
TI  - Schizophrenia: manifestations and course in different cultures. A World Health Organization ten-country study
CY  - Cambridge
PB  - Cambridge University Press
PY  - 1992
ER  - 
TY  - GEN
LB  - 37.
AU  - National Institute for Clinical Excellence
TI  - Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care
CY  - London
PB  - National Institute for Clinical Excellence
PY  - 1992
ER  - 
TY  - JOUR
LB  - 38.
AU  - Correll, CU
AU  - Leucht, S
AU  - Kane, JM
TI  - Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies
J2  - Am J Psychiatry
PY  - 2004
VL  - 161
SP  - 414
EP  - 425
ER  - 
TY  - JOUR
LB  - 39.
AU  - Kerwin, RW
TI  - The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research
J2  - Br J Psychiatry
PY  - 1994
VL  - 164
SP  - 141
EP  - 148
ER  - 
TY  - JOUR
LB  - 40.
AU  - Geddes, J
AU  - Freemantle, N
AU  - Harrison, P
AU  - Bebbington, P
TI  - Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
J2  - BMJ
PY  - 2000
VL  - 321
SP  - 1371
EP  - 1376
ER  - 
TY  - JOUR
LB  - 41.
AU  - Rosenheck, RA
AU  - Leslie, DL
AU  - Busch, S
AU  - Rofman, ES
AU  - Sernyak, M
TI  - Rethinking antipsychotic formulary policy
J2  - Schizophr Bull
PY  - 2008
VL  - 34
SP  - 375
EP  - 380
ER  - 
TY  - JOUR
LB  - 42.
AU  - Casey, DE
AU  - Haupt, DW
AU  - Newcomer, JW
AU  - Henderson, DC
AU  - Sernyak, MJ
AU  - Davidson, M
TI  - Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
J2  - J Clin Psychiatry
PY  - 2004
VL  - 65
IS  - Suppl. 7
SP  - 4
EP  - 18
ER  - 
TY  - JOUR
LB  - 43.
AU  - Lieberman, JA
AU  - Stroup, TS
AU  - McEvoy, JP
AU  - Swartz, MS
AU  - Rosenheck, RA
AU  - Perkins, DO
TI  - Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
J2  - N Engl J Med
PY  - 2005
VL  - 353
SP  - 1209
EP  - 1223
ER  - 
TY  - BOOK
LB  - 44.
AU  - Mehta, D
TI  - British national formulary
CY  - London
PB  - Pharmaceutical Press
PY  - 2007
ER  - 
TY  - JOUR
LB  - 45.
AU  - Iqbal, MM
AU  - Rahman, A
AU  - Husain, Z
AU  - Mahmud, SZ
AU  - Ryan, WG
AU  - Feldman, JM
TI  - Clozapine: a clinical review of adverse effects and management
J2  - Ann Clin Psychiatry
PY  - 2003
VL  - 15
SP  - 33
EP  - 48
ER  - 
TY  - BOOK
LB  - 46.
AU  - Taylor, D
AU  - Paton, C
AU  - Kerwin, R
TI  - The Maudsley prescribing guidelines
ET  - 9th
CY  - London
PB  - Routledge
PY  - 2007
ER  - 
TY  - JOUR
LB  - 47.
AU  - Bagnall, AM
AU  - Jones, L
AU  - Ginnelly, L
AU  - Lewis, R
AU  - Glanville, J
AU  - Gilbody, S
TI  - A systematic review of atypical antipsychotic drugs in schizophrenia
J2  - Health Technol Assess
PY  - 2003
VL  - 7
SP  - 1
EP  - 193
ER  - 
TY  - JOUR
LB  - 48.
AU  - Jones, PB
AU  - Barnes, TRE
AU  - Davies, L
AU  - Dunn, G
AU  - Lloyd, H
AU  - Hayhurst, KP
TI  - Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
J2  - Arch Gen Psychiatry
PY  - 2006
VL  - 63
SP  - 1079
EP  - 1087
ER  - 
TY  - JOUR
LB  - 49.
AU  - Lewis, S
AU  - Lieberman, J
TI  - CATIE and CUtLASS: can we handle the truth?
J2  - Br J Psychiatry
PY  - 2008
VL  - 192
SP  - 161
EP  - 163
ER  - 
TY  - JOUR
LB  - 50.
AU  - Hegarty, JD
AU  - Baldessarini, RJ
AU  - Tohen, M
AU  - Waternaux, C
AU  - Oepen, G
TI  - One hundred years of schizophrenia: a meta-analysis of the outcome literature
J2  - Am J Psychiatry
PY  - 1994
VL  - 151
SP  - 1409
EP  - 1416
ER  - 
TY  - JOUR
LB  - 51.
AU  - Tsoi, WF
AU  - Wong, KE
TI  - A 15-year follow-up study of Chinese schizophrenic patients
J2  - Acta Psychiatr Scand
PY  - 1991
VL  - 84
SP  - 217
EP  - 220
ER  - 
TY  - BOOK
LB  - 52.
AU  - Johnstone, E
AU  - Lawrie, S
AU  - Cunningham-Owens, DG
AU  - Sharpe, MD
TI  - Companion to psychiatric studies (MRCPsy study guides)
ET  - 7th
CY  - Oxford
PB  - Churchill Livingstone
PY  - 2004
ER  - 
TY  - JOUR
LB  - 53.
AU  - Meltzer, HY
TI  - Treatment of the neuroleptic-nonresponsive schizophrenic patient
J2  - Schizophr Bull
PY  - 1992
VL  - 18
SP  - 515
EP  - 542
ER  - 
TY  - JOUR
LB  - 54.
AU  - Johnstone, EC
AU  - Owens, DG
AU  - Leary, J
TI  - Disabilities and circumstances of schizophrenic patients – a follow-up study. Comparison of the 1975–85 cohort with the 1970–75 cohort
J2  - Br J Psychiatry
PY  - 1991
VL  - 13
IS  - Suppl.
SP  - 34
EP  - 36
ER  - 
TY  - JOUR
LB  - 55.
AU  - Mason, P
AU  - Harrison, G
AU  - Glazebrook, C
AU  - Medley, I
AU  - Dalkin, T
AU  - Croudace, T
TI  - Characteristics of outcome in schizophrenia at 13 years
J2  - Br J Psychiatry
PY  - 1995
VL  - 167
SP  - 596
EP  - 603
ER  - 
TY  - JOUR
LB  - 56.
AU  - Lieberman, J
AU  - Jody, D
AU  - Geisler, S
AU  - Alvir, J
AU  - Loebel, A
AU  - Szymanski, S
TI  - Time course and biologic correlates of treatment response in first-episode schizophrenia
J2  - Arch Gen Psychiatry
PY  - 1993
VL  - 50
SP  - 369
EP  - 376
ER  - 
TY  - JOUR
LB  - 57.
AU  - Conley, RR
AU  - Buchanan, RW
TI  - Evaluation of treatment-resistant schizophrenia
J2  - Schizophr Bull
PY  - 1997
VL  - 23
SP  - 663
EP  - 674
ER  - 
TY  - JOUR
LB  - 58.
AU  - Kane, JM
TI  - Management strategies for the treatment of schizophrenia
J2  - J Clin Psychiatry
PY  - 1999
VL  - 60
IS  - Suppl. 12
SP  - 13
EP  - 17
ER  - 
TY  - JOUR
LB  - 59.
AU  - Pantelis, C
AU  - Barnes, TR
TI  - Drug strategies and treatment-resistant schizophrenia [see comment]
J2  - Aust N Z J Psychiatry
PY  - 1996
VL  - 30
SP  - 20
EP  - 37
ER  - 
TY  - JOUR
LB  - 60.
AU  - Pantelis, C
AU  - Lambert, TJR
TI  - Managing patients with ‘treatment-resistant’ schizophrenia
J2  - Med J Aust
PY  - 2003
VL  - 178
IS  - Suppl.
SP  - S62
EP  - S66
ER  - 
TY  - JOUR
LB  - 61.
AU  - Herz, MI
AU  - Glazer, WM
AU  - Mostert, MA
AU  - Sheard, MA
AU  - Szymanski, HV
AU  - Hafez, H
TI  - Intermittent vs maintenance medication in schizophrenia. Two-year results
J2  - Arch Gen Psychiatry
PY  - 1991
VL  - 48
SP  - 333
EP  - 339
ER  - 
TY  - JOUR
LB  - 62.
AU  - Jolley, AG
AU  - Hirsch, SR
AU  - Morrison, E
AU  - McRink, A
AU  - Wilson, L
TI  - Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years
J2  - BMJ
PY  - 1990
VL  - 301
SP  - 837
EP  - 842
ER  - 
TY  - JOUR
LB  - 63.
AU  - Weiden, PJ
TI  - Understanding and addressing adherence issues in schizophrenia: from theory to practice
J2  - J Clin Psychiatry
PY  - 2007
VL  - 68
IS  - Suppl. 14
SP  - 14
EP  - 19
ER  - 
TY  - JOUR
LB  - 64.
AU  - Wyatt, RJ
TI  - Neuroleptics and the natural course of schizophrenia
J2  - Schizophr Bull
PY  - 1991
VL  - 17
SP  - 325
EP  - 351
ER  - 
TY  - JOUR
LB  - 65.
AU  - Leucht, S
AU  - Heres, S
TI  - Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia
J2  - J Clin Psychiatry
PY  - 2006
VL  - 67
IS  - Suppl. 5
SP  - 3
EP  - 8
ER  - 
TY  - JOUR
LB  - 66.
AU  - Kikkert, MJ
AU  - Barbui, C
AU  - Koeter, MW
AU  - David, AS
AU  - Leese, M
AU  - Tansella, M
TI  - Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research
J2  - J Nerv Ment Dis
PY  - 2008
VL  - 196
SP  - 274
EP  - 281
ER  - 
TY  - JOUR
LB  - 67.
AU  - Nose, M
AU  - Barbui, C
AU  - Tansella, M
TI  - How often do patients with psychosis fail to adhere to treatment programmes? A systematic review
J2  - Psychol Med
PY  - 2003
VL  - 33
SP  - 1149
EP  - 1160
ER  - 
TY  - JOUR
LB  - 68.
AU  - Lacro, JP
AU  - Dunn, LB
AU  - Dolder, CR
AU  - Leckband, SG
AU  - Jeste, DV
TI  - Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature
J2  - J Clin Psychiatry
PY  - 2002
VL  - 63
SP  - 892
EP  - 909
ER  - 
TY  - JOUR
LB  - 69.
AU  - Awad, G
TI  - Antipsychotic medications: compliance and attitudes towards treatment
J2  - Curr Opin Psychiatry
PY  - 2004
VL  - 17
SP  - 75
EP  - 80
ER  - 
TY  - JOUR
LB  - 70.
AU  - Farran-Ridge, C
TI  - Dementia praecox and epidemic encephalitis
J2  - J Med Sci
PY  - 1926
VL  - 72
SP  - 513
EP  - 523
ER  - 
TY  - JOUR
LB  - 71.
AU  - Owens, DG
AU  - Johnstone, EC
AU  - Frith, CD
TI  - Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics
J2  - Arch Gen Psychiatry
PY  - 1982
VL  - 39
SP  - 452
EP  - 461
ER  - 
TY  - JOUR
LB  - 72.
AU  - Correll, CU
AU  - Schenk, EM
TI  - Tardive dyskinesia and new antipsychotics
J2  - Curr Opin Psychiatry
PY  - 2008
VL  - 21
SP  - 151
EP  - 156
ER  - 
TY  - JOUR
LB  - 73.
AU  - Keshava, C
AU  - McCanlies, EC
AU  - Weston, A
TI  - CYP3A4 polymorphisms – potential risk factors for breast and prostate cancer: a HuGE review
J2  - Am J Epidemiol
PY  - 2004
VL  - 160
SP  - 825
EP  - 841
ER  - 
TY  - JOUR
LB  - 74.
AU  - Yu, AM
AU  - Fukamachi, K
AU  - Krausz, KW
AU  - Cheung, C
AU  - Gonzalez, FJ
TI  - Potential role for human cytochrome P450 3A4 in estradiol homeostasis
J2  - Endocrinology
PY  - 2005
VL  - 146
SP  - 2911
EP  - 2919
ER  - 
TY  - JOUR
LB  - 75.
AU  - Thummel, KE
AU  - Wilkinson, GR
TI  - In vitro and in vivo drug interactions involving human CYP3A
J2  - Annu Rev Pharmacol Toxicol
PY  - 1998
VL  - 38
SP  - 389
EP  - 430
ER  - 
TY  - JOUR
LB  - 76.
AU  - Faber, MS
AU  - Jetter, A
AU  - Fuhr, U
TI  - Assessment of CYP1A2 activity in clinical practice: Why, how, and when?
J2  - Basic Clin Pharmacol Toxicol
PY  - 2005
VL  - 97
SP  - 125
EP  - 134
ER  - 
TY  - JOUR
LB  - 77.
AU  - Patsopoulos, NA
AU  - Ntzani, EE
AU  - Zintzaras, E
AU  - Ioannidis, JPA
TI  - CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis
J2  - Pharmacogenet Genomics
PY  - 2005
VL  - 15
SP  - 151
EP  - 158
ER  - 
TY  - JOUR
LB  - 78.
AU  - Davies, T
TI  - Psychosocial factors and relapse of schizophrenia
J2  - BMJ
PY  - 1994
VL  - 309
SP  - 353
EP  - 354
ER  - 
TY  - RPRT
LB  - 79.
AU  - HM Treasury
TI  - Budget 2008: stability and opportunity: building a strong, sustainable future: economic and fiscal strategy report and financial statement and budget report
CY  - London
PB  - London Stationery Office
PY  - 2008
ER  - 
TY  - JOUR
LB  - 80.
AU  - Moher, D
AU  - Cook, J
AU  - Eastwood, S
AU  - Olkin, I
AU  - Rennie, D
AU  - Stroup, D
TI  - Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
J2  - Lancet
PY  - 1999
VL  - 354
SP  - 1896
EP  - 1900
ER  - 
TY  - ELEC
LB  - 81.
AU  - Little, J
AU  - Higgins, J
TI  - The HuGENet HUGE Review Handbook, version 1.0
PY  - 2006
UR  - www.genesens.net/_intranet/doc_nouvelles/HuGE%20Review%20Handbook%20v11.pdf
M1  - 30 June 2008
ER  - 
TY  - BOOK
LB  - 82.
AU  - Khan, K
AU  - Ter Riet, G
AU  - Glanville, J
AU  - Sowdon, A
AU  - Kleijnen, J
TI  - Undertaking systematic reviews of research on effectiveness. CRD’s guidance for carrying out or commissioning reviews
ET  - 2nd
CY  - York
PB  - Centre for Reviews and Dissemination, University of York
PY  - 2001
ER  - 
TY  - ELEC
LB  - 83.
AU  - Jorgensen, AL
AU  - Williamson, PR
TI  - Methodological quality of pharmacogenetic studies: issues of concern
TI  - Stat Med
PY  - 2008
UR  - 10.1002/sim.3420
ER  - 
TY  - JOUR
LB  - 84.
AU  - Higgins, JPT
AU  - Thompson, SG
AU  - Deeks, JJ
AU  - Altman, DG
TI  - Measuring inconsistency in meta-analysis
J2  - BMJ
PY  - 2003
VL  - 327
SP  - 557
EP  - 560
ER  - 
TY  - JOUR
LB  - 85.
AU  - Drummond, M
AU  - Jefferson, T
TI  - Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working
J2  - BMJ
PY  - 1996
VL  - 313
SP  - 275
EP  - 283
ER  - 
TY  - JOUR
LB  - 86.
AU  - Chou, WH
AU  - Yan, FX
AU  - Robbins-Weilert, DK
AU  - Ryder, TB
AU  - Liu, WW
AU  - Perbost, C
TI  - Comparison of two CYP2D6 genotyping methods and assessment of genotype–phenotype relationships
J2  - Clin Chem
PY  - 2003
VL  - 49
SP  - 542
EP  - 551
ER  - 
TY  - JOUR
LB  - 87.
AU  - Crescenti, A
AU  - Mas, S
AU  - Gasso, P
AU  - Baiget, M
AU  - Bernardo, M
AU  - Lafuente, A
TI  - Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis
J2  - Clin Exp Pharmacol Physiol
PY  - 2007
VL  - 34
SP  - 992
EP  - 997
ER  - 
TY  - JOUR
LB  - 88.
AU  - Dukek, BA
AU  - O’Kane, DJ
TI  - Comparison of Roche diagnostics AmpliChip CYP450IVD test with TM Bioscience Tag-It cytochrome P450 2D6 and 2C19 tests
J2  - Clin Chem
PY  - 2006
VL  - 52
SP  - A52-A
ER  - 
TY  - JOUR
LB  - 89.
AU  - Eriksson, S
AU  - Berg, LM
AU  - Wadelius, M
AU  - Alderborn, A
TI  - Cytochrome P450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology
J2  - Assay Drug Dev Technol
PY  - 2002
VL  - 1
SP  - 49
EP  - 59
ER  - 
TY  - JOUR
LB  - 90.
AU  - Heller, T
AU  - Kirchheiner, J
AU  - Armstrong, VW
AU  - Lathe, H
AU  - Brockmoller, J
AU  - Oellerich, M
TI  - Assessment of Amplichip CYP450-based CYP2D6-genotyping and phenotype prediction compared to PCR-RFLP-genotyping and phenotyping by metoprolol pharmacokinetics
J2  - Ther Drug Monit
PY  - 2005
VL  - 27
SP  - 221
ER  - 
TY  - JOUR
LB  - 91.
AU  - Heller, T
AU  - Kirchheiner, J
AU  - Armstrong, VW
AU  - Luthe, H
AU  - Tzvetkov, M
AU  - Brockmoller, J
TI  - AmpliChip CYP450 GeneChip®: a new gene chip that allows rapid and accurate CYP2D6 genotyping
J2  - Ther Drug Monit
PY  - 2006
VL  - 28
SP  - 673
EP  - 677
ER  - 
TY  - JOUR
LB  - 92.
AU  - Hersberger, M
AU  - Marti-Jaun, J
AU  - Rentsch, K
AU  - Hanseler, E
TI  - Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
J2  - Clin Chem
PY  - 2000
VL  - 46
SP  - 1072
EP  - 1077
ER  - 
TY  - JOUR
LB  - 93.
AU  - James, HM
AU  - Coller, JK
AU  - Gillis, D
AU  - Bahnisch, J
AU  - Sallustio, BC
AU  - Somogyi, AA
TI  - A new simple diagnostic for the identification of the major CYP2D6 genotypes by DNA sequencing analysis
J2  - Int J Clin Pharmacol Ther
PY  - 2004
VL  - 42
SP  - 719
EP  - 723
ER  - 
TY  - JOUR
LB  - 94.
AU  - Lee, HK
AU  - Lewis, LD
AU  - Tsongalis, GJ
AU  - Schur, BC
AU  - Jannetto, PJ
AU  - Wong, SH
TI  - Validation of a CYP2D6 genotyping panel on the NanoChip Molecular Biology Workstation
J2  - Clin Chem
PY  - 2007
VL  - 53
SP  - 823
EP  - 828
ER  - 
TY  - JOUR
LB  - 95.
AU  - Melis, R
AU  - Lyon, E
AU  - McMillin, GA
TI  - Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays
J2  - Exp Rev Mol Diagn
PY  - 2006
VL  - 6
SP  - 811
EP  - 820
ER  - 
TY  - JOUR
LB  - 96.
AU  - Muller, B
AU  - Zopf, K
AU  - Bachofer, J
AU  - Steimer, W
TI  - Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR
J2  - Clin Chem
PY  - 2003
VL  - 49
SP  - 1624
EP  - 1631
ER  - 
TY  - JOUR
LB  - 97.
AU  - Neville, M
AU  - Selzer, R
AU  - Aizenstein, B
AU  - Maguire, M
AU  - Hogan, K
AU  - Walton, R
TI  - Characterization of cytochrome P450 2D6 alleles using the Invader system
J2  - Biotechniques
PY  - 2002
IS  - Suppl.
SP  - 34
EP  - 38
ER  - 
TY  - JOUR
LB  - 98.
AU  - Nielsen, KA
AU  - Hansen, EL
AU  - Gille, S
TI  - Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes
J2  - Scand J Clin Lab Invest
PY  - 2007
VL  - 67
SP  - 280
EP  - 290
ER  - 
TY  - JOUR
LB  - 99.
AU  - Roberts, R
AU  - Sullivan, P
AU  - Joyce, P
AU  - Kennedy, MA
TI  - Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction
J2  - Hum Mutat
PY  - 2000
VL  - 16
SP  - 77
EP  - 85
ER  - 
TY  - ELEC
LB  - 100.
AU  - Roche Molecular Systems
TI  - US Food and Drug Administration 510(k) substantial equivalence determination decision summary for Roche AmpliChip CYP450 microarray for identifying CYP2D6 genotype (510(k) Number k042259)
UR  - www.fda.gov/cdrh/reviews/k042259.pdf
ER  - 
TY  - JOUR
LB  - 101.
AU  - Schaeffeler, E
AU  - Schwab, M
AU  - Eichelbaum, M
AU  - Zanger, UM
TI  - CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR
J2  - Hum Mutat
PY  - 2003
VL  - 22
SP  - 476
EP  - 485
ER  - 
TY  - JOUR
LB  - 102.
AU  - Soderback, E
AU  - Zackrisson, A-L
AU  - Lindblom, B
AU  - Alderborn, A
TI  - Determination of CYP2D6 gene copy number by pyrosequencing
J2  - Clin Chem
PY  - 2005
VL  - 51
SP  - 522
EP  - 531
ER  - 
TY  - JOUR
LB  - 103.
AU  - Stamer, UM
AU  - Stuber, F
TI  - Genetic factors in pain and its treatment
J2  - Curr Opin Anaesthesiol
PY  - 2007
VL  - 20
SP  - 478
EP  - 484
ER  - 
TY  - JOUR
LB  - 104.
AU  - Stuven, T
AU  - Griese, EU
AU  - Kroemer, HK
AU  - Eichelbaum, M
AU  - Zanger, UM
TI  - Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction
J2  - Pharmacogenetics
PY  - 1996
VL  - 6
SP  - 417
EP  - 421
ER  - 
TY  - JOUR
LB  - 105.
AU  - Zackrisson, A-L
AU  - Lindblom, B
TI  - Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing
J2  - Eur J Clin Pharmacol
PY  - 2003
VL  - 59
SP  - 521
EP  - 526
ER  - 
TY  - JOUR
LB  - 106.
AU  - Casley, WL
AU  - LeBlanc-Westwood, CA
TI  - Assay for the simultaneous detection of the *1C and *1F alleles of the CYP1A2 gene by real-time polymerase chain reaction and melting curve analysis
J2  - Psychiatr Genet
PY  - 2006
VL  - 16
SP  - 81
EP  - 83
ER  - 
TY  - JOUR
LB  - 107.
AU  - Popp, J
AU  - Messner, B
AU  - Steimer, W
TI  - High-speed genotyping of CYP1A2*1F mutation with fluorescent hybridization probes using the LightCycler
J2  - Pharmacogenomics
PY  - 2003
VL  - 4
SP  - 643
EP  - 646
ER  - 
TY  - JOUR
LB  - 108.
AU  - Burian, M
AU  - Grosch, S
AU  - Tegeder, I
AU  - Geisslinger, G
TI  - Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population
J2  - Br J Clin Pharmacol
PY  - 2002
VL  - 54
SP  - 518
EP  - 521
ER  - 
TY  - JOUR
LB  - 109.
AU  - Pickering, JW
AU  - McMillin, GA
AU  - Gedge, F
AU  - Hill, HR
AU  - Lyon, E
TI  - Flow cytometric assay for genotyping cytochrome P450 2C9 and 2C19: comparison with a microelectronic DNA array
J2  - Am J Pharmacogenomics
PY  - 2004
VL  - 4
SP  - 199
EP  - 207
ER  - 
TY  - JOUR
LB  - 110.
AU  - Toriello, M
AU  - Meccariello, P
AU  - Mazzaccara, C
AU  - Di Fiore, R
AU  - Esposito, C
AU  - Sacchetti, L
TI  - Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms
J2  - Clin Chem Lab Med
PY  - 2006
VL  - 44
SP  - 285
EP  - 287
ER  - 
TY  - JOUR
LB  - 111.
AU  - Wen, SY
AU  - Wang, H
AU  - Sun, OJ
AU  - Wang, SQ
TI  - Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray
J2  - World J Gastroenterol
PY  - 2003
VL  - 9
SP  - 1342
EP  - 1346
ER  - 
TY  - JOUR
LB  - 112.
AU  - Zainuddin, Z
AU  - Teh, LK
AU  - Suhaimi, AWM
AU  - Salleh, MZ
AU  - Ismail, R
TI  - A simple method for the detection of CYP2C9 polymorphisms: nested allele-specific multiplex polymerase chain reaction
J2  - Clin Chim Acta
PY  - 2003
VL  - 336
SP  - 97
EP  - 102
ER  - 
TY  - JOUR
LB  - 113.
AU  - Mizugaki, M
AU  - Hiratsuka, M
AU  - Agatsuma, Y
AU  - Matsubara, Y
AU  - Fujii, K
AU  - Kure, S
TI  - Rapid detection of CYP2C18 genotypes by real-time fluorescence polymerase chain reaction
J2  - J Pharm Pharmacol
PY  - 2000
VL  - 52
SP  - 199
EP  - 205
ER  - 
TY  - JOUR
LB  - 114.
AU  - Bruning, T
AU  - Abel, J
AU  - Koch, B
AU  - Lorenzen, K
AU  - Harth, V
AU  - Donat, S
TI  - Real-time PCR-analysis of the cytochrome P450 1B1 codon 432-polymorphism
J2  - Arch Toxicol
PY  - 1999
VL  - 73
SP  - 427
EP  - 430
ER  - 
TY  - JOUR
LB  - 115.
AU  - Fredericks, S
AU  - Moreton, M
AU  - MacPhee, IAM
AU  - Mohamed, M
AU  - Marlowe, S
AU  - Jorga, A
TI  - Genotyping cytochrome P450 3A5 using the light cycler
J2  - Ann Clin Biochem
PY  - 2005
VL  - 42
SP  - 376
EP  - 381
ER  - 
TY  - JOUR
LB  - 116.
AU  - Harth, V
AU  - Bruning, T
AU  - Abel, J
AU  - Koch, B
AU  - Berg, I
AU  - Sachinidis, A
TI  - Real-time genotyping of cytochrome P4501A1 A4889G and T6235C polymorphisms
J2  - Mol Cell Probes
PY  - 2001
VL  - 15
SP  - 93
EP  - 97
ER  - 
TY  - JOUR
LB  - 117.
AU  - Innocenti, C
AU  - Accorsi, A
AU  - Cerreta, V
AU  - Mantovani, V
AU  - Violante, FS
TI  - Fast CYP2E1 genotyping using automated fluorescent detection
J2  - Med Lav
PY  - 2006
VL  - 97
SP  - 799
EP  - 804
ER  - 
TY  - JOUR
LB  - 118.
AU  - Labuda, D
AU  - Krajinovic, M
AU  - Richer, C
AU  - Skoll, A
AU  - Sinnett, H
AU  - Yotova, V
TI  - Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay
J2  - Anal Biochem
PY  - 1999
VL  - 275
SP  - 84
EP  - 92
ER  - 
TY  - JOUR
LB  - 119.
AU  - Muthiah, YD
AU  - Lee, WL
AU  - Teh, LK
AU  - Ong, CE
AU  - Salleh, MZ
AU  - Ismail, R
TI  - A simple multiplex PCR method for the concurrent detection of three CYP2C8 variants
J2  - Clin Chim Acta
PY  - 2004
VL  - 349
SP  - 191
EP  - 198
ER  - 
TY  - JOUR
LB  - 120.
AU  - Oyama, T
AU  - Mitsudomi, T
AU  - Kawamoto, T
AU  - Ogami, A
AU  - Osaki, T
AU  - Kodama, Y
TI  - Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese
J2  - Int Arch Occup Environ Health
PY  - 1995
VL  - 67
SP  - 253
EP  - 256
ER  - 
TY  - JOUR
LB  - 121.
AU  - Rohrbacher, M
AU  - Kirchhof, A
AU  - Geisslinger, G
AU  - Lotsch, J
TI  - Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance
J2  - Pharmacogenomics
PY  - 2006
VL  - 7
SP  - 995
EP  - 1002
ER  - 
TY  - JOUR
LB  - 122.
AU  - Weise, A
AU  - Grundler, S
AU  - Zaumsegel, D
AU  - Klotzek, M
AU  - Grondahl, B
AU  - Forst, T
TI  - Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping
J2  - Clin Lab
PY  - 2004
VL  - 50
SP  - 141
EP  - 148
ER  - 
TY  - JOUR
LB  - 123.
AU  - Weise, A
AU  - Lambertz, U
AU  - Thome, N
AU  - Bartz, U
AU  - Krefft, M
AU  - Mockenhaupt, F
TI  - A fast and reliable single-run method for genotyping of the human cytochrome P450 2C8 gene for different ethnic groups
J2  - Clin Lab
PY  - 2006
VL  - 52
SP  - 599
EP  - 603
ER  - 
TY  - JOUR
LB  - 124.
AU  - Wen, S
AU  - Wang, H
AU  - Ding, Y
AU  - Liang, H
AU  - Wang, S
TI  - Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray
J2  - Genet Test
PY  - 2004
VL  - 8
SP  - 411
EP  - 416
ER  - 
TY  - JOUR
LB  - 125.
AU  - Wu, X
AU  - Zhou, Y
AU  - Xu, S
TI  - Detection of CYP I A1 polymorphisms with a colorimetric method based on mismatch hybridization
J2  - Clin Chim Acta
PY  - 2002
VL  - 323
SP  - 103
EP  - 109
ER  - 
TY  - JOUR
LB  - 126.
AU  - Aitchison, KJ
AU  - Munro, J
AU  - Wright, P
AU  - Smith, S
AU  - Makoff, AJ
AU  - Sachse, C
TI  - Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation
J2  - Br J Clin Pharmacol
PY  - 1999
VL  - 48
SP  - 388
EP  - 394
ER  - 
TY  - JOUR
LB  - 127.
AU  - Andreassen, OA
AU  - MacEwan, T
AU  - Gulbrandsen, AK
AU  - McCreadie, RG
AU  - Steen, VM
TI  - Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
J2  - Psychopharmacology (Berl)
PY  - 1997
VL  - 131
SP  - 174
EP  - 179
ER  - 
TY  - JOUR
LB  - 128.
AU  - Armstrong, M
AU  - Daly, AK
AU  - Blennerhassett, R
AU  - Ferrier, N
AU  - Idle, JR
TI  - Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype [see comment]
J2  - Br J Psychiatry
PY  - 1997
VL  - 170
SP  - 23
EP  - 26
ER  - 
TY  - JOUR
LB  - 129.
AU  - Arranz, MJ
AU  - Dawson, E
AU  - Shaikh, S
AU  - Sham, P
AU  - Sharma, T
AU  - Aitchison, K
TI  - Cytochrome P4502D6 genotype does not determine response to clozapine
J2  - Br J Clin Pharmacol
PY  - 1995
VL  - 39
SP  - 417
EP  - 420
ER  - 
TY  - JOUR
LB  - 130.
AU  - Arthur, H
AU  - Dahl, ML
AU  - Siwers, B
AU  - Sjoqvist, F
TI  - Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
J2  - J Clin Psychopharmacol
PY  - 1995
VL  - 15
SP  - 211
EP  - 216
ER  - 
TY  - JOUR
LB  - 131.
AU  - Brockmoller, J
AU  - Kirchheiner, J
AU  - Schmider, J
AU  - Walter, S
AU  - Sachse, C
AU  - Muller-Oerlinghausen, B
TI  - The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment
J2  - Clin Pharmacol Ther
PY  - 2002
VL  - 72
SP  - 438
EP  - 452
ER  - 
TY  - JOUR
LB  - 132.
AU  - Culav-Sumic, J
AU  - Topic, E
AU  - Baric, V
AU  - Stefanovic, M
AU  - Martic-Biocina, S
AU  - Skocic, D
TI  - CYP2D6 polymorphism and side effects in schizophrenia and schizoaffective psychosis
J2  - Period Biol
PY  - 2001
VL  - 103
SP  - 315
EP  - 319
ER  - 
TY  - JOUR
LB  - 133.
AU  - de Leon, J
AU  - Diaz, FJ
AU  - Wedlund, P
AU  - Josiassen, RC
AU  - Cooper, TB
AU  - Simpson, GM
TI  - Haloperidol half-life after chronic dosing
J2  - J Clin Psychopharmacol
PY  - 2004
VL  - 24
SP  - 656
EP  - 660
ER  - 
TY  - JOUR
LB  - 134.
AU  - Dettling, M
AU  - Sachse, C
AU  - Muller-Oerlinghausen, B
AU  - Roots, I
AU  - Brockmoller, J
AU  - Rolfs, A
TI  - Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P450206
J2  - Pharmacopsychiatry
PY  - 2000
VL  - 33
SP  - 218
EP  - 220
ER  - 
TY  - JOUR
LB  - 135.
AU  - Ellingrod, VL
AU  - Schultz, SK
AU  - Arndt, S
TI  - Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score
J2  - Psychiatr Genet
PY  - 2000
VL  - 10
SP  - 9
EP  - 11
ER  - 
TY  - JOUR
LB  - 136.
AU  - Ellingrod, VL
AU  - Miller, D
AU  - Schultz, SK
AU  - Wehring, H
AU  - Arndt, S
TI  - CYP2D6 polymorphisms and atypical antipsychotic weight gain
J2  - Psychiatr Genet
PY  - 2002
VL  - 12
SP  - 55
EP  - 58
ER  - 
TY  - JOUR
LB  - 137.
AU  - Ellingrod, VL
AU  - Schultz, SK
AU  - Arndt, S
TI  - Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6
J2  - Pharmacotherapy
PY  - 2002
VL  - 22
SP  - 1416
EP  - 1419
ER  - 
TY  - JOUR
LB  - 138.
AU  - Fu, Y
AU  - Fan, C-H
AU  - Deng, H-H
AU  - Hu, S-H
AU  - Lv, D-P
AU  - Li, L-H
TI  - Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients
J2  - Acta Pharm Sinica
PY  - 2006
VL  - 27
SP  - 328
EP  - 332
ER  - 
TY  - JOUR
LB  - 139.
AU  - Hamelin, BA
AU  - Dorson, PG
AU  - Pabis, D
AU  - Still, D
AU  - Bouchard, RH
AU  - Pourcher, E
TI  - CYP2D6 mutations and therapeutic outcome in schizophrenic patients
J2  - Pharmacotherapy
PY  - 1999
VL  - 19
SP  - 1057
EP  - 1063
ER  - 
TY  - JOUR
LB  - 140.
AU  - Inada, T
AU  - Senoo, H
AU  - Iijima, Y
AU  - Yamauchi, T
AU  - Yagi, G
TI  - Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients
J2  - Psychiatr Genet
PY  - 2003
VL  - 13
SP  - 163
EP  - 168
ER  - 
TY  - JOUR
LB  - 141.
AU  - Iwahashi, K
AU  - Isobe, C
AU  - Waga, C
TI  - The influence that the polymorphisms of cytochrome P450 (CYP) gene, thrifty gene and pharmacodynamic-related gene give to a side effect of olanzapine
J2  - Int Clin Psychopharmacol
PY  - 2007
VL  - 22
SP  - P21
ER  - 
TY  - JOUR
LB  - 142.
AU  - Jaanson, P
AU  - Marandi, T
AU  - Kiivet, RA
AU  - Vasar, V
AU  - Vaan, S
AU  - Svensson, JO
TI  - Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype
J2  - Psychopharmacology (Berl)
PY  - 2002
VL  - 162
SP  - 67
EP  - 73
ER  - 
TY  - JOUR
LB  - 143.
AU  - Jeon, JY
AU  - Kim, JR
AU  - Lim, KS
AU  - Kim, JW
AU  - Kim, BH
AU  - Tae, YM
TI  - CYP2D6 genotype affects aripiprazole clearance in Korean patients: population pharmacokinetic analysis
J2  - Clin Pharmacol Ther
PY  - 2007
VL  - 81
SP  - S80
ER  - 
TY  - JOUR
LB  - 144.
AU  - Jerling, M
AU  - Dahl, ML
AU  - Aberg-Wistedt, A
AU  - Liljenberg, B
AU  - Landell, NE
AU  - Bertilsson, L
TI  - The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol
J2  - Clin Pharmacol Ther
PY  - 1996
VL  - 59
SP  - 423
EP  - 428
ER  - 
TY  - JOUR
LB  - 145.
AU  - Kakihara, S
AU  - Yoshimura, R
AU  - Shinkai, K
AU  - Matsumoto, C
AU  - Goto, M
AU  - Kaji, K
TI  - Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6
J2  - Int Clin Psychopharmacol
PY  - 2005
VL  - 20
SP  - 71
EP  - 78
ER  - 
TY  - JOUR
LB  - 146.
AU  - Kapitany, T
AU  - Meszaros, K
AU  - Lenzinger, E
AU  - Schindler, SD
AU  - Barnas, C
AU  - Fuchs, K
TI  - Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
J2  - Schizophr Res
PY  - 1998
VL  - 32
SP  - 101
EP  - 106
ER  - 
TY  - JOUR
LB  - 147.
AU  - Lam, LC
AU  - Garcia-Barcelo, MM
AU  - Ungvari, GS
AU  - Tang, WK
AU  - Lam, VK
AU  - Kwong, SL
TI  - Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients
J2  - Pharmacopsychiatry
PY  - 2001
VL  - 34
SP  - 238
EP  - 241
ER  - 
TY  - JOUR
LB  - 148.
AU  - Lane, HY
AU  - Liu, YC
AU  - Huang, CL
AU  - Chang, YC
AU  - Wu, PL
AU  - Lu, CT
TI  - Risperidone-related weight gain – genetic and nongenetic predictors
J2  - J Clin Psychopharmacol
PY  - 2006
VL  - 26
SP  - 128
EP  - 134
ER  - 
TY  - JOUR
LB  - 149.
AU  - Liou, YJ
AU  - Wang, YC
AU  - Bai, YM
AU  - Lin, CC
AU  - Yu, SC
AU  - Liao, DL
TI  - Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients
J2  - Neuropsychobiology
PY  - 2004
VL  - 49
SP  - 167
EP  - 173
ER  - 
TY  - JOUR
LB  - 150.
AU  - Lohmann, PL
AU  - Bagli, M
AU  - Krauss, H
AU  - Muller, DJ
AU  - Schulze, TG
AU  - Fangerau, H
TI  - CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients
J2  - Pharmacopsychiatry
PY  - 2003
VL  - 36
SP  - 73
EP  - 78
ER  - 
TY  - JOUR
LB  - 151.
AU  - Mihara, K
AU  - Kondo, T
AU  - Higuchi, H
AU  - Takahashi, H
AU  - Yoshida, K
AU  - Shimizu, T
TI  - Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D-2 and D-3 receptors: a preliminary finding
J2  - Am J Med Genet
PY  - 2002
VL  - 114
SP  - 693
EP  - 695
ER  - 
TY  - JOUR
LB  - 152.
AU  - Nikoloff, D
AU  - Shim, JC
AU  - Fairchild, M
AU  - Patten, N
AU  - Fijal, BA
AU  - Koch, WH
TI  - Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics
J2  - Pharmacogenomics J
PY  - 2002
VL  - 2
SP  - 400
EP  - 407
ER  - 
TY  - JOUR
LB  - 153.
AU  - Ohmori, O
AU  - Suzuki, T
AU  - Kojima, H
AU  - Shinkai, T
AU  - Terao, T
AU  - Mita, T
TI  - Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
J2  - Schizophr Res
PY  - 1998
VL  - 32
SP  - 107
EP  - 113
ER  - 
TY  - JOUR
LB  - 154.
AU  - Ohmori, O
AU  - Kojima, H
AU  - Shinkai, T
AU  - Terao, T
AU  - Suzuki, T
AU  - Abe, K
TI  - Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients
J2  - Psychiatry Res
PY  - 1999
VL  - 87
SP  - 239
EP  - 244
ER  - 
TY  - JOUR
LB  - 155.
AU  - Panagiotidis, G
AU  - Arthur, HW
AU  - Lindh, JD
AU  - Dahl, ML
AU  - Sjoqvist, F
TI  - Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome
J2  - Ther Drug Monit
PY  - 2007
VL  - 29
SP  - 417
EP  - 422
ER  - 
TY  - JOUR
LB  - 156.
AU  - Plesnicar, BK
AU  - Zalar, B
AU  - Breskvar, K
AU  - Dolzan, V
TI  - The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment
J2  - J Psychopharmacol (Oxf)
PY  - 2006
VL  - 20
SP  - 829
EP  - 833
ER  - 
TY  - JOUR
LB  - 157.
AU  - Riedel, M
AU  - Schwarz, MJ
AU  - Strassnig, M
AU  - Spellmann, I
AU  - Muller-Arends, A
AU  - Weber, K
TI  - Risperidone plasma levels, clinical response and side-effects
J2  - Eur Arch Psychiatry Clin Neurosci
PY  - 2005
VL  - 255
SP  - 261
EP  - 268
ER  - 
TY  - JOUR
LB  - 158.
AU  - Scordo, MG
AU  - Spina, E
AU  - Romeo, P
AU  - Dahl, ML
AU  - Bertilsson, L
AU  - Johansson, I
TI  - CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
J2  - Eur J Clin Pharmacol
PY  - 2000
VL  - 56
SP  - 679
EP  - 683
ER  - 
TY  - JOUR
LB  - 159.
AU  - Thanacoody, RHK
AU  - Daly, AK
AU  - Reilly, JG
AU  - Ferrier, IN
AU  - Thomas, SHL
TI  - Factors affecting drug concentrations and QT interval during thioridazine therapy
J2  - Clin Pharmacol Ther
PY  - 2007
VL  - 82
SP  - 555
EP  - 565
ER  - 
TY  - JOUR
LB  - 160.
AU  - Thanacoody, HKR
AU  - Daly, AK
AU  - Thomas, SHL
TI  - Influence of CYP2D6 and CYP2C19 genotypes on the QTc intervals of psychiatric patients taking thioridazine
J2  - Br J Clin Pharmacol
PY  - 2003
VL  - 55
SP  - 445
ER  - 
TY  - JOUR
LB  - 161.
AU  - Tiwari, AK
AU  - Deshpande, SN
AU  - Rao, AR
AU  - Bhatia, T
AU  - Lerer, B
AU  - Nimgaonkar, VL
TI  - Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms
J2  - Schizophr Res
PY  - 2005
VL  - 75
SP  - 21
EP  - 26
ER  - 
TY  - JOUR
LB  - 162.
AU  - Topic, E
AU  - Stefanovic, M
AU  - Ivanisevic, AM
AU  - Blazinic, F
AU  - Culav, J
AU  - Skocilic, Z
TI  - CYP2D6 genotyping in patients on psychoactive drug therapy
J2  - Clin Chem Lab Med
PY  - 2000
VL  - 38
SP  - 921
EP  - 927
ER  - 
TY  - JOUR
LB  - 163.
AU  - Wang, L
AU  - Yu, L
AU  - Zhang, AP
AU  - Fang, C
AU  - Du, J
AU  - Gu, NF
TI  - Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia
J2  - J Psychopharmacol (Oxf)
PY  - 2007
VL  - 21
SP  - 837
EP  - 842
ER  - 
TY  - JOUR
LB  - 164.
AU  - Basile, VS
AU  - Ozdemir, V
AU  - Masellis, M
AU  - Walker, ML
AU  - Meltzer, HY
AU  - Lieberman, JA
TI  - A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia
J2  - Mol Psychiatry
PY  - 2000
VL  - 5
SP  - 410
EP  - 417
ER  - 
TY  - JOUR
LB  - 165.
AU  - Boke, O
AU  - Gunes, S
AU  - Kara, N
AU  - Aker, S
AU  - Sahin, AR
AU  - Basar, Y
TI  - Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population
J2  - DNA Cell Biol
PY  - 2007
VL  - 26
SP  - 527
EP  - 531
ER  - 
TY  - JOUR
LB  - 166.
AU  - Matsumoto, C
AU  - Ohmori, O
AU  - Shinkai, T
AU  - Hori, H
AU  - Nakamura, J
TI  - Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia
J2  - Psychiatr Genet
PY  - 2004
VL  - 14
SP  - 209
EP  - 213
ER  - 
TY  - JOUR
LB  - 167.
AU  - Schulze, TG
AU  - Schumacher, J
AU  - Muller, DJ
AU  - Krauss, H
AU  - Alfter, D
AU  - Maroldt, A
TI  - Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia
J2  - Am J Med Genet
PY  - 2001
VL  - 105
SP  - 498
EP  - 501
ER  - 
TY  - JOUR
LB  - 168.
AU  - Tay, JKX
AU  - Tan, CH
AU  - Chong, SA
AU  - Tan, EC
TI  - Functional polymorphisms of the cytochrome P450 lA2 (CYPlA2) gene and prolonged QTc interval in schizophrenia
J2  - Prog Neuropsychopharmacol Biol Psychiatry
PY  - 2007
VL  - 31
SP  - 1297
EP  - 1302
ER  - 
TY  - JOUR
LB  - 169.
AU  - Tiwari, AK
AU  - Deshpande, SN
AU  - Rao, AR
AU  - Bhatia, T
AU  - Mukit, SR
AU  - Shriharsh, V
TI  - Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects. I. Association of CYP1A2 gene polymorphism
J2  - Pharmacogenomics J
PY  - 2005
VL  - 5
SP  - 60
EP  - 69
ER  - 
TY  - JOUR
LB  - 170.
AU  - Tiwari, AK
AU  - Deshpande, SN
AU  - Lerer, B
AU  - Nimgaonkar, VL
AU  - Thelma, BK
TI  - Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects. V. Association of CYP1A2 1545 C > T polymorphism
J2  - Pharmacogenomics J
PY  - 2007
VL  - 7
SP  - 305
EP  - 311
ER  - 
TY  - JOUR
LB  - 171.
AU  - Yasar, U
AU  - Babaoglu, MO
AU  - Balibey, H
AU  - Cetin, M
AU  - Lundgren, S
AU  - Rane, A
TI  - Association of the cytochrome P450 1A2*1F polymorphism with clozapine response in schizophrenic patients
J2  - FASEB J
PY  - 2007
VL  - 21
SP  - A196
ER  - 
TY  - JOUR
LB  - 172.
AU  - Segman, RH
AU  - Heresco-Levy, U
AU  - Yakir, A
AU  - Goltser, T
AU  - Strous, R
AU  - Greenberg, DA
TI  - Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia
J2  - Biol Psychiatry
PY  - 2002
VL  - 51
SP  - 261
EP  - 263
ER  - 
TY  - JOUR
LB  - 173.
AU  - Hutton, JL
AU  - Williamson, PR
TI  - Bias in meta-analysis due to outcome variable selection within studies
J2  - J R Stat Soc Ser C
PY  - 2000
VL  - 49
SP  - 359
EP  - 370
ER  - 
TY  - JOUR
LB  - 174.
AU  - Miles, W
AU  - Sheridan, J
AU  - Wheeler, A
TI  - The effect of knowing the CYP 450 metaboliser status on clinician prescribing behaviour when treating psychosis with risperidone
J2  - Aust N Z J Psychiatry
PY  - 2007
VL  - 41
SP  - A60
ER  - 
TY  - ELEC
LB  - 175.
AU  - Danish Institute for Health Services Research
TI  - Does genotyping for cytochrome P450 polymorphisms improve individual antipsycotic drug treatment? (2007–2011)
UR  - www.mrw.interscience.wiley.com/cochrane/clhta/articles/HTA-20061224/frame.html
ER  - 
TY  - JOUR
LB  - 176.
AU  - Mulder, H
AU  - Herder, A
AU  - Wilmink, FW
AU  - Tamminga, WJ
AU  - Belitser, SV
AU  - Egberts, ACG
TI  - The impact of cytochrome P450–2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice
J2  - Pharmacoepidemiol Drug Saf
PY  - 2006
VL  - 15
SP  - 107
EP  - 114
ER  - 
TY  - JOUR
LB  - 177.
AU  - Charlier, C
AU  - Broly, F
AU  - Lhermitte, M
TI  - Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine
J2  - Ther Drug Monit
PY  - 2003
VL  - 25
SP  - 738
EP  - 742
ER  - 
TY  - JOUR
LB  - 178.
AU  - Grasmader, K
AU  - Verwohlt, PL
AU  - Rietschel, M
AU  - Dragicevic, A
AU  - Müller, M
AU  - Hiemke, C
TI  - Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting
J2  - Eur J Clin Pharmacol
PY  - 2004
VL  - 60
SP  - 329
EP  - 336
ER  - 
TY  - JOUR
LB  - 179.
AU  - Rossini, D
AU  - Serretti, A
AU  - Franchini, L
AU  - Mandelli, L
AU  - Smeraldi, E
AU  - Rondi, D
TI  - Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial
J2  - J Clin Psychopharmacol
PY  - 2005
VL  - 25
SP  - 471
EP  - 475
ER  - 
TY  - ELEC
LB  - 180.
TI  - Anon
UR  - www.costco.com/pharmacy
M1  - 11 September 2006
ER  - 
TY  - ELEC
LB  - 181.
AU  - Palylyk Colwell, E
TI  - CYP450 genotyping for determining drug metabolizer status (structured abstract)
UR  - www.mrw.interscience.wiley.com/cochrane/clhta/articles/HTA-20060238/frame.html
M1  - 2006
ER  - 
TY  - JOUR
LB  - 182.
AU  - Bennett, KJ
AU  - Torrance, GW
AU  - Boyle, MH
AU  - Guscott, R
AU  - Moran, LA
TI  - Development and testing of a utility measure for major, unipolar depression
J2  - Q Life Res
PY  - 2000
VL  - 9
SP  - 109
EP  - 120
ER  - 
TY  - BOOK
LB  - 183.
AU  - Kind, P
AU  - Hardman, G
AU  - Macran, S
TI  - UK population norms for EQ-5D
CY  - York
PB  - Centre for Health Economics, University of York
PY  - 1999
ER  - 
TY  - JOUR
LB  - 184.
AU  - Hatziandreu, EJ
AU  - Brown, RE
AU  - Revicki, DA
AU  - Turner, R
AU  - Martindale, J
AU  - Levine, S
TI  - Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin
J2  - Pharmacoeconomics
PY  - 1994
VL  - 5
SP  - 249
EP  - 268
ER  - 
TY  - JOUR
LB  - 185.
AU  - Anton, SF
AU  - Revicki, DA
TI  - The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone
J2  - Psychopharmacol Bull
PY  - 1995
VL  - 31
SP  - 249
EP  - 258
ER  - 
TY  - JOUR
LB  - 186.
AU  - Tarrier, N
AU  - Barrowclough, C
AU  - Bamrah, JS
TI  - Prodromal signs of relapse in schizophrenia
J2  - Soc Psychiatry Psychiatr Epidemiol
PY  - 1991
VL  - 26
SP  - 157
EP  - 161
ER  - 
TY  - JOUR
LB  - 187.
AU  - Lieberman, J
AU  - Alvir, J
AU  - Geisler, S
AU  - Ramos-Lorenzi, J
AU  - Woerner, M
AU  - Novacenko, H
TI  - Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia
J2  - Neuropsychopharmacology
PY  - 1994
VL  - 11
SP  - 107
EP  - 118
ER  - 
TY  - JOUR
LB  - 188.
AU  - Doering, S
AU  - Müller, E
AU  - Köpcke, W
AU  - Pietzcker, A
AU  - Gaebel, W
AU  - Linden, M
TI  - Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder
J2  - Schizophr Bull
PY  - 1998
VL  - 24
SP  - 87
EP  - 98
ER  - 
TY  - JOUR
LB  - 189.
AU  - Swofford, CD
AU  - Kasckow, JW
AU  - Scheller-Gilkey, G
AU  - Inderbitzin, L
TI  - Substance use: a powerful predictor of relapse in schizophrenia
J2  - Schizophr Res
PY  - 1996
VL  - 20
SP  - 145
EP  - 151
ER  - 
TY  - CHAP
LB  - 190.
AU  - Goff, DC
AU  - Shader, RI
TI  - Non-neurological side-effects of antipsychotic drugs
A2  - Hirsch, SR
A2  - Weinberger, D
T2  - Schizophrenia
ET  - 2nd
CY  - Oxford
PB  - Blackwell Publishing
PY  - 2003
SP  - 573
EP  - 588
ER  - 
TY  - JOUR
LB  - 191.
AU  - Phelan, N
AU  - Stradins, L
AU  - Morrison, S
TI  - Physical health of people with severe mental illness
J2  - BMJ
PY  - 2001
VL  - 322
SP  - 442
EP  - 444
ER  - 
TY  - JOUR
LB  - 192.
AU  - Newman, SC
AU  - Bland, RC
TI  - Mortality in a cohort of patients with schizophrenia: a record linkage study
J2  - Can J Psychiatry
PY  - 1991
VL  - 36
SP  - 239
EP  - 254
ER  - 
TY  - JOUR
LB  - 193.
AU  - Brown, S
AU  - Inskip, H
AU  - Barraclough, B
TI  - Causes of the excess mortality of schizophrenia
J2  - Br J Psychiatry
PY  - 2000
VL  - 177
SP  - 212
EP  - 217
ER  - 
TY  - CHAP
LB  - 194.
AU  - Barnes, TR
AU  - Kerwin, R
TI  - Mortality and sudden death in schizophrenia
A2  - Camm, J
T2  - Cardiovascular risk associated with schizophrenia and its treatment
CY  - London
PB  - Galliard Healthcare Communications
PY  - 2003
SP  - 7
EP  - 23
ER  - 
TY  - JOUR
LB  - 195.
AU  - Cooper, D
AU  - Moisan, J
AU  - Grégoire, JP
TI  - Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia
J2  - J Clin Psychiatry
PY  - 2007
VL  - 68
SP  - 818
EP  - 825
ER  - 
TY  - JOUR
LB  - 196.
AU  - Morken, G
AU  - Widen, JH
AU  - Grawe, RW
TI  - Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia
J2  - BMC Psychiatry
PY  - 2008
VL  - 8
SP  - 32
ER  - 
TY  - JOUR
LB  - 197.
AU  - Tunis, SL
AU  - Faries, DE
AU  - Stensland, MD
AU  - Hay, DP
AU  - Kinon, BJ
TI  - An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia
J2  - Curr Med Res Opin
PY  - 2007
VL  - 23
SP  - 97
EP  - 104
ER  - 
TY  - JOUR
LB  - 198.
AU  - Gee, L
AU  - Pearce, E
AU  - Jackson, M
TI  - Quality of life in schizophrenia: a grounded theory approach
J2  - Health Qual Life Outcomes
PY  - 2003
VL  - 1
SP  - 31
ER  - 
TY  - GEN
LB  - 199.
AU  - National Collaborating Centre for Mental Health
TI  - Schizophrenia: full national clinical guideline on core interventions in primary and secondary care
CY  - London
PB  - Royal College of Psychiatrists and British Psychological Society
PY  - 2002
ER  - 
TY  - JOUR
LB  - 200.
AU  - Almond, S
AU  - O’Donnell, O
TI  - Cost analysis of the treatment of schizophrenia in the UK: a simulation model comprising olanzapine, risperidone and haloperidol
J2  - Pharmacoeconomics
PY  - 2000
VL  - 17
SP  - 383
EP  - 389
ER  - 
TY  - JOUR
LB  - 201.
AU  - Almond, S
AU  - O’Donnell, O
TI  - Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol
J2  - Pharmacoeconomics
PY  - 1998
VL  - 13
SP  - 575
EP  - 588
ER  - 
TY  - JOUR
LB  - 202.
AU  - Beard, AM
AU  - Maciver, F
AU  - Clouth, J
AU  - Ruther, E
TI  - A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany
J2  - Eur J Health Econ
PY  - 2006
VL  - 7
SP  - 165
EP  - 172
ER  - 
TY  - JOUR
LB  - 203.
AU  - Bernardo, M
AU  - Azanza, JR
AU  - Rubio-Terres, C
AU  - Rejas, J
TI  - Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study in Spain
J2  - Clin Drug Investig
PY  - 2006
VL  - 26
SP  - 447
EP  - 457
ER  - 
TY  - JOUR
LB  - 204.
AU  - Bernardo, M
AU  - Azanza, JR
AU  - Rubio-Terres, C
AU  - Rejas, J
TI  - Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS)
J2  - Actas Esp Psiquiatr
PY  - 2007
VL  - 35
SP  - 259
EP  - 262
ER  - 
TY  - JOUR
LB  - 205.
AU  - Bobes, J
AU  - Canas, F
AU  - Rejas, J
AU  - Mackell, J
TI  - Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain
J2  - Prog Neuropsychopharmacol Biol Psychiatry
PY  - 2004
VL  - 28
SP  - 1287
EP  - 1297
ER  - 
TY  - JOUR
LB  - 206.
AU  - Bounthavong, M
AU  - Okamoto, MP
TI  - Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia
J2  - J Eval Clin Pract
PY  - 2007
VL  - 13
SP  - 453
EP  - 460
ER  - 
TY  - JOUR
LB  - 207.
AU  - Byrom, BD
AU  - Garratt, CJ
AU  - Kilpatrick, AT
TI  - Influence of antipsychotic profile on cost of treatment of schizophrenia: a decision analysis approach
J2  - Int J Psychiatry Clin Pract
PY  - 1998
VL  - 2
SP  - 129
EP  - 138
ER  - 
TY  - BOOK
LB  - 208.
AU  - Davies, L
AU  - Lewis, S
TI  - Antipsychotic medication for people with first episode schizophrenia: an exploratory economic analysis of alternative treatment algorithms
CY  - York
PB  - Centre for Health Economics and School of Psychiatry and Behavioural Sciences, University of Manchester
PY  - 2000
ER  - 
TY  - JOUR
LB  - 209.
AU  - Davies, A
AU  - Langley, PC
AU  - Keks, NA
AU  - Catts, SV
AU  - Lambert, T
AU  - Schweitzer, I
TI  - Risperiodone versus haloperidol. II. Cost-effectiveness
J2  - Clin Ther
PY  - 1998
VL  - 20
SP  - 196
EP  - 213
ER  - 
TY  - JOUR
LB  - 210.
AU  - De Graeve, D
AU  - Smet, A
AU  - Mehnert, A
AU  - Caleo, S
AU  - Miadi-Fargier, H
AU  - Mosqueda, GJ
TI  - Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis
J2  - Pharmacoeconomics
PY  - 2005
VL  - 23
SP  - 35
EP  - 47
ER  - 
TY  - JOUR
LB  - 211.
AU  - Glazer, WM
AU  - Ereshefsky, L
TI  - A pharmacoeconomic model of outpatient antipsychotic therapy in ‘revolving door’ schizophrenic patients
J2  - J Clin Psychiatry
PY  - 1996
VL  - 57
SP  - 337
EP  - 345
ER  - 
TY  - JOUR
LB  - 212.
AU  - Edwards, NC
AU  - Rupnow, MFT
AU  - Pashos, CL
AU  - Botteman, MF
AU  - Diamond, RJ
TI  - Cost-effectiveness model of long-acting risperidone in schizophrenia in the US
J2  - Pharmacoeconomics
PY  - 2005
VL  - 23
SP  - 299
EP  - 314
ER  - 
TY  - JOUR
LB  - 213.
AU  - Obradovic, M
AU  - Mrhar, A
AU  - Kos, M
TI  - Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia
J2  - Int J Clin Pract
PY  - 2007
VL  - 61
SP  - 1979
EP  - 1988
ER  - 
TY  - JOUR
LB  - 214.
AU  - Ganguly, R
AU  - Miller, LS
AU  - Martin, BC
TI  - Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy
J2  - Schizophr Res
PY  - 2003
VL  - 63
SP  - 111
EP  - 119
ER  - 
TY  - BOOK
LB  - 215.
AU  - Glennie, JL
TI  - Pharmacoeconomic evaluations of clozapine in treatment resistant schizophrenia and risperidone in chronic schizophrenia
CY  - Ottawa
PB  - Canadian Coordinating Office for Health Technology Assessment
PY  - 1997
ER  - 
TY  - JOUR
LB  - 216.
AU  - Gutierrez-Recacha, P
AU  - Chisholm, D
AU  - Haro, JM
AU  - Salvador-Carulla, L
AU  - Ayuso-Mateos, JL
TI  - Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain
J2  - Acta Psychiatr Scand
PY  - 2006
VL  - 114
SP  - 29
EP  - 38
ER  - 
TY  - JOUR
LB  - 217.
AU  - Hansen, K
AU  - Francois, C
AU  - Toumi, M
AU  - Lancon, C
TI  - A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia
J2  - Eur J Health Econ
PY  - 2002
VL  - 3
SP  - 173
EP  - 179
ER  - 
TY  - JOUR
LB  - 218.
AU  - Heeg, BM
AU  - Buskens, E
AU  - Knapp, M
AU  - van Aalst, G
AU  - Dries, PJ
AU  - de Haan, L
TI  - Modelling the treated course of schizophrenia: development of a discrete event simulation model
J2  - Pharmacoeconomics
PY  - 2005
VL  - 23
SP  - 17
EP  - 33
ER  - 
TY  - JOUR
LB  - 219.
AU  - Kongsakon, R
AU  - Leelahanaj, T
AU  - Price, N
AU  - Birinyi-Strachan, L
AU  - Davey, P
TI  - Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol
J2  - J Med Assoc Thai
PY  - 2005
VL  - 88
SP  - 1267
EP  - 1277
ER  - 
TY  - JOUR
LB  - 220.
AU  - Launois, R
AU  - von der Schulenberg, MG
AU  - Knapp, M
AU  - Toumi, M
TI  - Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model
J2  - Int J Psychiatry Clin Pract
PY  - 1998
VL  - 2
SP  - S79
EP  - S86
ER  - 
TY  - JOUR
LB  - 221.
AU  - Laurier, C
AU  - Kennedy, W
AU  - Lachaine, J
AU  - Gariepy, L
AU  - Tessier, G
TI  - Economic evaluation of zuclopenthixol acetate compared with injectable haloperidol in schizophrenic patients with acute psychosis
J2  - Clin Ther
PY  - 1997
VL  - 19
SP  - 316
EP  - 329
ER  - 
TY  - JOUR
LB  - 222.
AU  - Lecomte, P
AU  - De Hert, M
AU  - van Dijk, M
AU  - Nuijten, M
AU  - Nuyts, G
AU  - Persson, U
TI  - A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium
J2  - Value Health
PY  - 2000
VL  - 3
SP  - 1
EP  - 11
ER  - 
TY  - JOUR
LB  - 223.
AU  - Magnus, A
AU  - Carr, V
AU  - Mihalopoulos, C
AU  - Carter, R
AU  - Vos, T
TI  - Assessing cost-effectiveness of drug interventions for schizophrenia
J2  - Aust N Z J Psychiatry
PY  - 2005
VL  - 39
SP  - 44
EP  - 54
ER  - 
TY  - JOUR
LB  - 224.
AU  - Mortimer, A
AU  - Williams, P
AU  - Meddis, D
TI  - Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost
J2  - J Int Med Res
PY  - 2003
VL  - 31
SP  - 188
EP  - 196
ER  - 
TY  - JOUR
LB  - 225.
AU  - Oh, PI
AU  - Iskedjian, M
AU  - Addis, A
AU  - Lanctot, K
AU  - Einarson, TR
TI  - Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis
J2  - Can J Clin Pharmacol
PY  - 2001
VL  - 8
SP  - 199
EP  - 206
ER  - 
TY  - JOUR
LB  - 226.
AU  - Oh, PI
AU  - Lanctot, KL
AU  - Mittmann, N
AU  - Iskedjian, M
AU  - Einarson, TR
TI  - Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia
J2  - J Med Econ
PY  - 2001
VL  - 4
SP  - 137
EP  - 156
ER  - 
TY  - JOUR
LB  - 227.
AU  - Palmer, CS
AU  - Revicki, DA
AU  - Genduso, LA
AU  - Hamilton, SH
AU  - Brown, RE
TI  - A cost-effectiveness clinical decision analysis model for schizophrenia
J2  - Am J Manag Care
PY  - 1998
VL  - 4
SP  - 345
EP  - 355
ER  - 
TY  - JOUR
LB  - 228.
AU  - Palmer, CS
AU  - Brunner, E
AU  - Ruiz-Flores, LG
AU  - Paez-Agraz, F
AU  - Revicki, DA
TI  - A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia
J2  - Arch Med Res
PY  - 2002
VL  - 33
SP  - 572
EP  - 580
ER  - 
TY  - JOUR
LB  - 229.
AU  - Sacristan, JA
AU  - Gomez, JC
AU  - Salvador-Carulla, L
TI  - Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia in Spain
J2  - Actas Luso Esp Neurol Psiquiatr Cienc Afines
PY  - 1997
VL  - 25
SP  - 225
EP  - 234
ER  - 
TY  - JOUR
LB  - 230.
AU  - Perlis, RH
AU  - Ganz, DA
AU  - Avorn, J
AU  - Schneeweiss, S
AU  - Glynn, RJ
AU  - Smoller, JW
TI  - Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model
J2  - J Clin Psychopharmacol
PY  - 2005
VL  - 25
SP  - 427
EP  - 434
ER  - 
TY  - JOUR
LB  - 231.
AU  - Tilden, D
AU  - Aristides, M
AU  - Meddis, D
AU  - Burns, T
TI  - An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics
J2  - Clin Ther
PY  - 2002
VL  - 24
SP  - 1648
EP  - 1667
ER  - 
TY  - JOUR
LB  - 232.
AU  - Vera-Llonch, M
AU  - Delea, TE
AU  - Richardson, E
AU  - Rupnow, M
AU  - Grogg, A
AU  - Oster, G
TI  - Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model
J2  - Value Health
PY  - 2004
VL  - 7
SP  - 569
EP  - 584
ER  - 
TY  - JOUR
LB  - 233.
AU  - Vera-Llonch, M
AU  - Delea, TE
AU  - Richardson, E
AU  - Oster, G
AU  - Rupnow, M
AU  - Grogg, A
TI  - Authors’ response to comments regarding risperidone versus olanzapine Markov model
J2  - Value Health
PY  - 2005
VL  - 8
SP  - 613
EP  - 614
ER  - 
TY  - JOUR
LB  - 234.
AU  - Wang, PS
AU  - Ganz, DA
AU  - Benner, JS
AU  - Glynn, RJ
AU  - Avorn, J
TI  - Should clozapine continue to be restricted to third-line status for schizophrenia: a decision-analytic model
J2  - J Ment Health Pol Econ
PY  - 2004
VL  - 7
SP  - 77
EP  - 85
ER  - 
TY  - JOUR
LB  - 235.
AU  - Yang, YK
AU  - Tarn, YH
AU  - Wang, TY
AU  - Liu, CY
AU  - Laio, YC
AU  - Chou, YH
TI  - Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs
J2  - Psychiatry Clin Neurosci
PY  - 2005
VL  - 59
SP  - 385
EP  - 394
ER  - 
TY  - GEN
LB  - 236.
TI  - Risperidone package insert (Risperdal; Janssen, US)
ER  - 
TY  - JOUR
LB  - 237.
AU  - Duggan, A
AU  - Warner, J
AU  - Knapp, M
AU  - Kerwin, R
TI  - Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK
J2  - Br J Psychiatry
PY  - 2003
VL  - 182
SP  - 505
EP  - 508
ER  -